June/July 2011 (vol. 08/1)

ContentsFeaturesNewsLegal NewsResearch DigestResearch PlusCPD

Research Plus

Treating chronic HCV infection

Adding the oral protease inhibitor boceprevir to standard therapy with peginterferon and ribavirin significantly improves viral suppression in adults with chronic hepatitis C infection genotype-1 (the most common UK genotype), according to two randomised, placebo-controlled clinical trials1,2. Current treatment regimens achieve sustained virological response (ie undetectable viral loads) of less than 50% for people with genotype-1 infection. The two studies examined people with untreated and previously treated chronic infection, respectively, with sustained virological responses of up to 68% and 75%, and significant improvements in previous non-responders. Response varied with ethnic group.

    1. New England Journal of Medicine 2011; 364(13): 1195–1206.
    2. New England Journal of Medicine 2011; 364(13): 1207–1217.
  • Tags

    Occupational Health at Work June/July 2011 (vol. 08/1) pp41